Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027
Olema Pharmaceuticals Inc. (NASDAQ: OLMA ) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027. Additionally, the company presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Me